While AS strategy has changed the treatment and management of low-risk prostate cancer.

While AS strategy has changed the treatment and management of low-risk prostate cancer, it must also to develop as a diagnostic tool. In fact, the proportion of patients treated due to upstaging or prostate – specific antigen increases during the follow-up is significant, because the lack of accurate initial staging. In this context, the investigation of the selection strategy for AS candidates is essential.

The risk of unfavorable disease by Gleason score u003e 7 and / or pT3-4 cancer ranges from 28.6 percent to 35, based on AS criteria in a 12 – core strategy is used as compared to 14.6 percent defined if the biopsy scheme is based on 21 cores.. The criteria for AS varies greatly among different series and centers without strong evidence-based data. These criteria are dependent on the core biopsy number. The results of our study out out, 14.6 percent extended biopsy strategy with 21 cores provides better pathologic assessment for men with low-risk prostate cancer than a 12 – core biopsy scheme and reduces the risk of incorrect assignment of patients with low-risk prostate cancer.Hundreds of delegates from across the UK that idofact one million female members of voted for a movement at idofact Women’s Conference, of the problem put is too high the agenda the EU.